Fewer Than 1 in 4 Patients With HCV-Related HCC Get DAAs
Early uncertainty about the safety of noninterferon antivirals in patients with liver cancer may have contributed to the slow acceptance of direct-acting antiviral agents in this population.
University Of California San Francisco United States Palo Alto Stanford University Steven Bollipo Leslie Yeeman Kam
Source: medscape.com